Feasibility Study of Adjuvant Chemotherapy of S-1 and Carboplatin for Completely Resected Non-Small Cell Lung Cancer

Publisher： Karger

E-ISSN： 1421-9794|59|1|35-41

ISSN： 0009-3157

Source： Chemotherapy, Vol.59, Iss.1, 2013-06, pp. : 35-41

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Phase II Study of First-Line Chemotherapy with Weekly Carboplatin Plus Gemcitabine in Advanced Non-Small Cell Lung Cancer

By  

Chemotherapy, Vol. 58, Iss. 1, 2012-02 ,pp. : 78-83

Karger

Access to resources Recommend Favorite

Prognostic Impact of the ABCC11/MRP8 Polymorphism in Adjuvant Oral Chemotherapy with S-1 for Non-Small Cell Lung Cancer

By  

Chemotherapy, Vol. 61, Iss. 2, 2015-0 ,pp. : 77-86

Karger

Access to resources Recommend Favorite

A Retrospective Study of the Novel Combination of Paclitaxel and S1 for Pretreated Advanced Non-Small Cell Lung Cancer

By  

Chemotherapy, Vol. 58, Iss. 6, 2013-01 ,pp. : 454-460

Karger

Access to resources Recommend Favorite

A Phase II Study of S-1 for Previously Untreated Elderly Patients with Advanced Non-Small Cell Lung Cancer

By  

Chemotherapy, Vol. 61, Iss. 2, 2015-0 ,pp. : 93-98

Karger

Access to resources Recommend Favorite

A Phase II Study Directed by a Clinical Pathway for Carboplatin and Weekly Paclitaxel in Previously Untreated Patients with Unresectable Non-Small Cell Lung Cancer

By  

Chemotherapy, Vol. 56, Iss. 1, 2010-02 ,pp. : 39-45

Karger

Access to resources Recommend Favorite